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1. Introduction  
Glucocorticoids are used in the treatment of inflammatory and autoimmune diseases, 
cancers, and following organ transplantation. Glucocorticoid-induced osteoporosis is one of 
the primary side effects of glucocorticoid use resulting in increased risk of fractures. In a 
large meta-analysis study of glucocorticoid users, for example, van Staa et al (2002) found a 
relative risk increase of 1.91 for any fracture, 2.86 for vertebral fracture, 1.61 for hip fracture, 
and 1.13 for forearm fracture. Glucocorticoid-induced osteoporosis is characterized by low 
bone turnover and fractures, which occur in 30-50% of patients (van Staa et al., 2000). 
Glucocorticoids affect predominantly cancellous or trabecular bone, increasing the risk of 
vertebral fractures, which may be asymptomatic and occur early during the first months of 
glucocorticoid treatment (Laan et al., 1993; van Staa et al., 2000) and (Angeli et al., 2006). 
Trabecular bone accounts for approximately 20% of the total mass of bone (Bertazzo & 
Bertran, 2006) and also contributes to the ability of bone to tolerate stress to avoid fracture, 
especially in the spine. Long-term use of glucocorticoids also increases the risk of all 
osteoporotic fractures.  
Published reports suggest no course of glucocorticoid therapy is safe for the skeleton. 
Regimens of daily prednisone at doses as low as 2.5 mg have been associated with an 
increased risk of hip and vertebral fractures. The risk increases by 5-fold, with prednisone 
doses above 7.5 mg daily. A dramatic 17-fold increase in vertebral fracture incidence was 
observed in subjects who used prednisone continuously more than 10 mg per day for longer 
than 3 months with increased fracture incidence in postmenopausal females and elderly 
males. The risk of osteoporotic fractures was also elevated in patients undergoing cyclic 
corticosteroid treatment at high doses (Van Staa et al., 2006) Although variable in onset, 
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fracture risk decreases after discontinuation of oral corticosteroids (Vestergaard et al., 2008). 
The risk of osteoporosis associated with inhaled glucocorticoids or with budesonide, a 
topical steroid used in inflammatory bowel disease, is small because their absorption is 
limited. Due to the high risk of fracture in glucocorticoid-administered patients, treatment 
guidelines exist.  
Treatment guidelines for the use of glucocorticoids have been established which advise that 
if prednisolone is administered at ≥ 5 mg per day for three months or longer requires 
regular monitoring of bone mineral density (BMD) and treatment to prevent osteoporosis 
must be initiated (American college of Rheumatology, 2001; Adler & Hochberg, 2003; 
National Osteoporosis Society, 1998). Vitamin D and calcium are also recommended for the 
management of all patients treated with glucocorticoids. Bisphosphonates should be 
considered for the prevention and treatment of this disorder, because they can prevent the 
initial loss of bone mass from glucocoriticoids. Alendronate, risedronate, and zoledronic 
acid were shown to prevent and reverse the loss of BMD in glucocorticoid-induced 
osteoporosis with greater effects than those observed with vitamin D and calcium (Doga et 
al., 2008) and (Amin et al., 2002). In fact, bisphosphonates induce improvement of BMD that 
is 2-fold greater than that observed during vitamin D treatment alone (4.6% vs. 2.0%, 
respectively) (Amin et al., 2002). Anabolic therapy is also utilized for treatment of 
glucocorticoid-induced osteoporosis. Teriparatide causes a greater increase in BMD than 
alendronate and greater reduction in the risk of vertebral fractures (Saag et al., 2007). Even 
with these evidentiary clinical trials and guidelines, patient bone loss is, in general, poorly 
managed (Eastell et al., 1998; Walsh et al., 1996; Gudbjornsson et al., 2002). In glucocorticoid-
induced osteoporosis, fractures also occur at higher BMDs than in postmenopausal 
osteoporosis in untreated women (van Staa et al., 2003). Consequently, guidelines for the 
treatment of postmenopausal osteoporosis are not applicable to glucocorticoid-induced 
osteoporosis, and patients should be treated at BMD T-scores of ≤−1.0 to −1.5 (Compston, 
2004). In addition, vertebral fractures may be asymptomatic and often require radiological 
diagnosis before treatment. Since the incidence of fractures is higher in the spine compared 
to other areas of the body, glucocorticoid therapy appears to affect rapid bone remodelling. 
During the initial phases of glucocorticoid exposure bone resorption is increased (van Staa 
et al., 2000). Glucocorticoids inhibit the formation of mature osteoblasts, but also activate 
apoptosis in these cell types (Jones & Sambrook, 1994; Canalis et al., 2007). Osteoprotegrin 
(OPG) expression, a key factor involved in modulating maturation of osteoclasts, is reduced 
also by glucocorticoids resulting in increased osteoclastogenesis (Orcel, 2005). Therefore, the 
combination of reduced osteoblast formation, increased osteoclast maturation leads to 
accelerated bone loss while on glucocorticoid therapy. Therapies are needed which 
modulate osteoclast as well as osteoblast activity to restore a more normal balance to the 
bone remodeling process in glucocorticoid treated patients.  
2. Glucocorticoid-induced osteoporosis: Is there a role for genistein? 
Among the anabolic compounds tested in recent years genistein aglycone seems a 
promising agent able to stimulate bone formation and to reduce bone resorption, acting 
via a genomic as well as a non-genomic pathways. Genistein is an isoflavone found in 
small quantities in certain legumes throughout the plant kingdom. Soybeans are a 
particularly rich source of genistin, the glucosidal precursor of genistein, although the 
concentration varies with the strain, location and environmental conditions of cultivation 
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of the plant. Another widely utilized source of genistin is Sophora japonica L (Tian et al., 
2004). The glucosidal form and acetyl- and malonyl-glucosides are the major isoforms 
found in soybean derivates. The conversion from the glucosides to the aglycone form 
occurs in the gut, where the sugar residue is removed with the generation of genistein 
(Larkin et al., 2008).  
Genistein is freely absorbed from the intestine and a large fraction is converted to the 7β-O-
glucuronide as it crosses the brush border and ultimately enters the portal vein (Sfakianos et 
al., 1997), a process that is influenced by intestinal bacteria (Setchell et al., 2002; Day et al., 
1998). Recent ex vivo data using isolated human gastrointestinal tract tissue also suggest that 
genistein may also undergo sulfonation in the small intestine, though the extent to which 
these sulfonates are absorbed following dietary intake is unknown (Ronis et al., 2006). The 
exact percentages of glucuronidated and sulfonated metabolites after crossing the lumen are 
also unknown, although it is clear that only a small percentage of the parent molecule 
remains as unconjugated genistein once it reaches the liver. Once in the liver, genistein 
undergoes additional biotransformation via CYP450-mediated hydroxylation (Hu et al., 
2003) followed by glucuronidation and sulfonation by UDP-glucuronosyl transferase and 
sulphotransferases, respectively (Sfakianos et al. 1997). Genistein 7β-O-glucuronide can be 
recovered from bile after infusion of genistein into the small bowel of rats (Prasain et al., 
2006). As much as 70% of the recovered genistein from bile is in the form of glucuronidated 
conjugates with smaller amounts reappearing in the distal duodenum and jejunum 
(Sfakianos et al., 1997). The vast majority of circulating genistein in serum has been found to 
be in the form of glucuronidated and sulfonated conjugates which represent excretion forms 
of the molecule (Setchell et al., 2002). Little is known about the bioactivity of conjugated 
isoflavones. Genistein is composed of two benzene rings (A and B) linked through a 
heterocyclic pyrane C ring. The hydroxyl group on the A ring confers to genistein a greater 
activity both in vitro and in vivo, compared to other isoflavones (Choi et al., 2008). 
In addition to competing with endogenous estrogens for binding to the estrogen receptors at 
high concentrations, genistein may exert anti-estrogenic effects by several potential 
mechanisms (Tham et al., 1998). Genistein has both ER agonist and antagonist activity in 
different cell types and works in a promoter specific manner in gene activation via ERs. The 
ER domain structure is typical of nuclear receptors. The amino-terminal region is involved 
in trans-activation of gene expression and has been termed the activation function domain 
or AF1 domain. The middle region contains a two-zinc finger structure, which plays an 
important role in binding to specific DNA response elements and in receptor dimerization. 
The carboxyl-terminal region contains an activation domain, termed AF2. A ligand binding 
domain, lying within AF2, is crucial for binding to receptor specific ligands and also co-
repressors and co-activators. This binding interaction affects receptor dimerization, nuclear 
translocation and modulation of target gene expression by AF2. The ligand-binding domain 
is structurally conserved among the nuclear receptor family and consists of between 10 and 
12α helices folded in a globular domain. A central hydrophobic pocket accommodates the 
cognate ligand, which upon binding induces a conformational change in the ligand-binding 
domain, exposing a coactivator-docking site on ligand binding surface. However the 
binding of SERMs to ERs results in a different conformation change in which the 
coactivator-binding site is blocked from interaction with coactivator, thereby blocking AF2 
mediated transcriptional activity (Liu et al., 2003). Several classes of nuclear receptor 
coactivators interact with ERs receptors and are specific for either ERα or ERβ. Using 
specifying coactivator recruitment and fluorescence resonance energy transfer, the genistein 
www.intechopen.com
 
Basic and Clinical Endocrinology Up-to-Date 
 
292 
interaction with ER receptors was investigated (Kuiper et al., 1998). Compounds with 
estrogen agonism induce agonist-mediated recruitment and allow fluorescence resonance 
energy transfer. Compounds with estrogen antagonism block the agonist-mediated 
recruitment of coactivators and prevents fluorescence resonance energy transfer. Genistein 
showed full agonism for ER α and only partial agonism for ER β, but higher affinity for ERβ 
than ERα (Kuiper et al., 1998). 
A second action of genistein on membrane associated protein (membrane receptors) has 
been proposed, and remains still not fully elucidated. In this mechanism, several possible 
second messengers, including kinase enzymes, are activated and in turn stimulate or inhibit 
downstream pathways of metabolism and protein products. The duration of this effect via a 
membrane protein is short lasting and of limited efficacy. The positive effects of genistein on 
primary osteoporosis, due to estrogen fall, have been extensively investigated by our group 
as well as by others and have been recently summarized in a review article (Bitto et al., 
2010); however pre-clinical evidence point out a role for genistein also in secondary 
osteoporosis induced by corticosteroid use.  
2.1 Evidence from in vitro studies 
Genistein has been most investigated for its effect on the proliferation and differentiation of 
a number of cell types. Through its effect on tyrosine kinase, genistein is able to modulate 
cell cycle progression in the S phase, to induce G2/M arrest and to induce apoptosis 
(Matsukawa et al., 1993). Numerous in vitro studies with human or animal osteoclast- or 
osteoblast-like cell lines have been carried out with consistent observations of direct effects 
of genistein on both cell types. Effects of genistein on bone metabolism derived from direct 
and indirect actions on bone cells and can be summarized in stimulation of osteoblastic bone 
formation and inhibition of osteoclastic bone resorption (Gao & Yamaguchi, 1999a; 
Sugimoto & Yamaguchi, 2000; Chen et al., 2003; Heim et al., 2004). In vitro studies indicate 
that genistein is able to stimulate osteoblastic activity and inhibit osteoclast formation and 
action at a range of concentrations (10−5–10−7 M) consistent with the levels observed in 
human subjects after ingestion of genistein. With regard to effects on osteoclast genistein 
inhibits their formation and function (Amano et al., 1998; Gao & Yamaguchi, 2000; 
Yamagishi et al., 2001; Albertazzi, 2002; Blair et al., 1996; Gao & Yamaguchi, 1999a; Kajiya et 
al, 2000; Williams et al, 1998). Genistein suppress osteoclast activity by a number of possible 
mechanisms, including induction of apoptosis, activation of protein tyrosine phosphatase, 
inhibition of cytokines, changes in intracellular Ca2+, and membrane depolarization. More in 
details, in mouse marrow cultures genistein has a potent inhibitory effect on osteoclast-like 
cell formation, and this effect is similar to others anti-bone-resorbing agents, such as 
calcitonin and 17β-estradiol, and may involve cAMP signaling. Sliwiñski and coworkers 
(2005) compared the effects of genistein, estradiol and raloxifene, compounds affecting in 
different ways estrogen receptors, on formation and viability of osteoclast from neonatal rat 
bone marrow; the results shown that all treatments decrease the number of osteoclasts 
formed from bone marrow, particularly genistein at the lower concentration decreases the 
number of osteoclasts by induction cell death, while at higher concentration genistein 
prevents the formation of osteoclasts. These observations are consistent with the results of 
another study (Rickard et al. 2003), showing that genistein, acting as agonist of estrogen 
receptors, mimicked estradiol in affecting gene expression of progesterone receptor, the 
proteoglycan versican, alkaline phosphatase and osteopontin, and production of 
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interleukin-6 protein. However, actions of genistein at the cellular level depend on the target 
tissue, receptor status of the tissue, and the level of endogenous estrogen. Both estrogen 
receptors ERα and ERβ are present in bone tissue, although the expression of these subtypes 
varies considerably during differentiation. The greatly increased expression of ERβ during 
bone mineralization is particularly pertinent to the potential hormonal effects of isoflavones 
because compounds such as genistein show a much higher affinity for ERβ than for ERα 
(Arts et al., 1997). 
One of the mechanism by which genistein induces apoptosis of mature osteoclasts involves 
the Ca2+ signaling, the inhibition of protein kinase and the activation of protein tyrosine 
phosphatase in osteoclasts. In this study the suppressive effect of genistein was completely 
abolished by the presence of inhibitors of Ca2+-dependent protein kinases (Gao & 
Yamaguchi, 1999b). The most important cytokine machinery, which is involved in bone 
metabolism, is osteoprotegerin (OPG)/receptor activator of nuclear factor-κB 
(RANK)/RANK ligand (RANKL) system. The molecular triad OPG/RANK/RANKL plays 
important roles in bone remodeling. RANKL is expressed by osteoblasts and is necessary 
and sufficient for osteoclastogenesis. RANKL binds to its receptor RANK, present at the 
surface of osteoclast precursors and mature osteoclasts, inducing osteoclast formation and 
activation. RANKL activity can be blocked by the soluble decoy receptor OPG, resulting in 
prevention of bone resorption. Studies, in vitro, have found that genistein induces apoptosis 
and inhibits RANKL signaling-related gene expression (Uchiyama & Yamaguchi, 2007). 
Genistein was also reported to increase osteoblastic differentiation and affect osteoblast 
activity (Rickard et al., 2003; Pan et al., 2005; Morris et al., 2006; Okumura et al., 2006). In 
osteoblasts genistein stimulates a concentration-dependent increase in alkaline phosphatase 
activity. In osteoblastic MC3T3-E1 cells, genistein increases protein content, DNA content 
and alkaline phosphatase activity (Yamaguchi & Sugimoto, 2000; Sugimoto & Yamaguchi, 
2000). This effect has also been demonstrated in tissue cultures. In femoral metaphyseal 
tissue from elderly female rats genistein increases Ca2+ content and alkaline phosphatase 
activity. This effect is blocked by tamoxifen, indicating an ER-mediated pathway, and also 
by cycloheximide, suggesting that this isoflavone influence transcriptional or translational 
events (Yamaguchi & Gao, 1997, 1998). On the other hand, genistein also causes apoptosis of 
osteoblasts by activating caspase-3 and cleaving adhesion molecules such as cadherins and 
catenins (Hunter et al., 2001). In normal fetal osteoblast cells, genistein increases the 
progesterone receptor and alkaline phosphatase gene expression and inhibits osteopontin 
and interleukin-6 gene expression (Rickard et al. 2003).  
2.2 Evidence from in vivo studies 
The manner by which glucocorticoids induce bone loss is complex and incompletely 
understood (Patschan et al., 2001; Canalis et al., 2007), in part because there are no animal 
models absolutely comparable to humans. A major effect on the skeleton is a decrease in 
bone formation and unchanged or enhanced bone resorption (Lane et al., 2001). The main 
effect of glucocorticoids on bone is inhibition of osteoblastogenesis, augmented continued 
osteoclastogenesis and osteocyte apoptosis, leading to a decrease in bone formation, a rapid 
weakening of bone architecture and an increase in fracture risk (Manolagas & Weinstein, 
1999). Chronic administration of steroids also causes avascular necrosis via an apoptotic 
mechanism of osteocytes and osteoblasts (Weinstein et al., 2000, Bekler et al., 2007). Once 
osteonecrosis occurs, glucocorticoids also cause inhibition of bone regeneration (Takano-
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Murakami et al., 2009). In a rat model, we studied genistein preservative effects on 
methylprednisolone-induced bone loss and osteonecrosis of the femoral head (Bitto et al., 
2009). In our study (Figure 1), genistein succeeded in preventing osteoporosis and 
osteonecrosis of the femoral head when co-administered with the glucocorticoid. The 
isoflavone statistically maintained bone mineral density (Figure 2) and content (Bitto et 
al., 2009) over the methylprednisolone-treated group and showed comparable efficacy 
with the vehicle group. Genistein co-administered with methylprednisolone also 
statistically maintained femoral bone’s resistance to rupture compared with the 
methylprednisolone group (Figure 3C) and preserved the normal architecture of cartilage 
as well as both cortical and trabecular bones with a well-organized matrix in femoral head 
(Figure 3 A and B).  
 
Vehicle
(n=7)
Methylprednisolone
(n=7)
Methylprednisolone
+ Genistein (n=7)
Sacrifice, assessment of final BMD and BMC. Evaluation of
breaking strength, biochemical and histological assays.
Assessment of Basal BMD and BMC 
Time of treatment
60 days
Genistein
(n=7)
 
Fig. 1. Flow-chart of the experimental protocol. 
 
 
Fig. 2. Effects of aglycone genistein on femoral bone mineral density (BMD) in 
methylprednisolone-treated rats. Data are shown as % of variation from basal values in the 
same group of animals. * p<0.005 vs. methylprednisolone. 
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Fig. 3. A and B: Light microscopy of the bone structure of the femur head obtained from 
animals treated with methylprednisolone (A) or methylprednisolone plus genistein 
aglycone (B). (H&E original magnification X5). C: Femur breaking strength: *p<0.001 vs. 
methylprednisolone. Data are shown as % of variation from vehicle treated animals. 
In addition, genistein caused a significant increase in b-ALP and OPG over 
methylprednisolone and vehicle confirming its role as an anabolic bone-forming agent 
(Figure 4A and B). Genistein administration also significantly reduced CTX circulating 
levels suggesting an anti-resorptive effect (Figure 4C).  
Corticosteroid therapy has been shown to cause apoptosis in osteoblasts and inhibit the 
production of OPG required for bone formation, while RANKL accumulates resulting in 
further bone resorption (Bejar et al. 2005). Genistein has been shown to stimulate the 
production of osteoblasts via inhibition of a RANKL-resorptive mechanism by producing 
OPG (Viereck et al. 2002). This was also confirmed in our study where genistein increased 
OPG levels in glucocorticoid-treated animals. Osteoprotegrin is a glycoprotein secreted by 
osteoblasts in a differentiation-dependent manner and acts as a ‘decoy receptor’ (a soluble 
receptor that acts as antagonist) for RANKL regulating osteoclast functions and lifespan. In 
postmenopausal women with bone loss, genistein stimulated the production of OPG, down-
regulated RANKL and decreased the RANKL/OPG ratio suggesting a direct effect on the 
RANK cytokine system (Marini et al., 2008). This work on genistein also suggests that 
increases in OPG in humans modulates the maturation process of osteoclast formation, thus 
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clarifying the putative antiresorptive effect being a non-apoptotic process, rather than an 
apoptotic process induced in antiresorptive therapy with bisphosphonates. Other 
mechanisms of genistein binding to glucocorticoid receptors have also been implicated.  
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Fig. 4. A-C: Effects of aglycone genistein on serum bone-alkaline phosphatase (b-ALP), 
osteoprotegerin (OPG) and collagen C-telopeptides (CTX). Data are shown as % of variation 
from vehicle treated animals. b-ALP: * p<0.005 vs methylprednisolone. OPG: *p<0.001 vs. 
methylprednisolone. CTX: *p<0.001 vs. methylprednisolone.  
It has been demonstrated that genistein inhibits glucocorticoid receptor transactivation and 
may also induce a proteosomal degradation of the glucocorticoid receptor complex via the 
p53 and ubiquitin pathways (Kinyamu & Archer 2003). Another mechanism might involve 
genistein activity as a tyrosine kinase inhibitor via the limitation of the subcellular nuclear 
transport and the recycling of the glucocorticoid receptors, blunting in turn the effects of 
glucocorticoids on bone (Yang et al., 1997).  
3. Conclusions 
Several studies and reports show a decrease in BMD and an increased risk of fractures 
during glucocorticoid use as well as an increase in osteonecrosis with chronic steroid use. 
Approximately 30% of all fractures of the hip and almost half of all fractures of the spine can 
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be attributed to chronic, high-dose glucocorticoid administration in humans (van Staa et al., 
2001). Prior and current exposure to glucocorticoids increases the risk of fractures beyond 
that explained by values of BMD (Civitelli & Ziambaras, 2008). Pharmacological 
intervention for prevention of glucocorticoid-induced osteoporosis is needed depending on 
dose, expected duration of treatment, age and gender of the patient, and sometimes BMD at 
the start of the glucocorticoid therapy. At present, calcium and vitamin D3 supplementation 
are considered as important support for the prevention of glucocorticoid-induced 
osteoporosis (Williams et al., 2004). Bisphosphonates are largely used to avoid bone loss and 
are cost effective in certain subgroups of patients depending on age, gender, glucocorticoid 
dose, and previous fracture history (Williams et al., 2004; Prinsloo & Hosking, 2006). 
Unfortunately, calcium and vitamin D3 supplementation may not be enough to stave off 
bone deterioration and bisphosphonates have safety risks associated with long-term use, 
such as esophageal burns, bone and muscular pain (Ettinger et al., 1998; Wysowski & 
Chang, 2005). Osteonecrosis of the jaw, although rare and found primarily in cancer patients 
undergoing dental surgery, is a very serious and debilitating side effect of bisphosphonate 
use (Durie et al., 2005). Therefore, a safe and effective treatment for the prevention of bone 
loss and osteonecrosis of the femoral head in glucocorticoid-treated subjects is still needed.  
Collectively, our results strongly suggest that genistein might be a new potential therapy for 
the prevention of glucocorticoid-induced osteoporosis, the most important secondary cause 
of osteoporosis in humans. And in the minority of cases, genistein may prevent necrotic 
deterioration of the femoral head. Usually, drugs used in management of osteoporosis have 
been classified as predominantly ‘antiresorptive agents’ or as ‘bone-forming agents’, but, on 
the basis of the present results, genistein might represent the first therapy to overcome this 
classification combining a powerful bone-forming as well as an anti-resorptive activity. 
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